Molecular profiles of endometrial cancer tumors among Black patients

Annelise M. Wilhite; Yasmine Baca; Joanne Xiu; Rajesh Paladugu; Adam C. ElNaggar; Jubilee Brown; Ira S. Winer; Robert Morris; Britt K. Erickson; Alexander B. Olawaiye; Matthew Powell; W. Michael Korn; Rodney P. Rocconi; Dineo Khabele; Nathaniel L. Jones

doi:10.1016/j.ygyno.2022.04.014

Molecular profiles of endometrial cancer tumors among Black patients

Annelise M. Wilhite, Yasmine Baca, Joanne Xiu, Rajesh Paladugu, Adam C. ElNaggar, Jubilee Brown, Ira S. Winer, Robert Morris, Britt K. Erickson, Alexander B. Olawaiye, Matthew Powell, W. Michael Korn, Rodney P. Rocconi, Dineo Khabele, Nathaniel L. Jones

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

OBJECTIVES: Disparate outcomes exist between Black and White patients with endometrial cancer (EC). One contributing factor is the disproportionately low representation of Black patients in clinical trials and in tumor molecular profiling studies. Our objective was to investigate molecular profiles of ECs in a cohort with a high proportion of tumors from Black patients.

METHODS: A total of 248 EC samples and self-reported race data were collected from 6 institutions. Comprehensive tumor profiling and analyses were performed by Caris Life Sciences.

RESULTS: Tumors from 105 (42%) Black and 143 (58%) White patients were included. Serous histology (58% vs 36%) and carcinosarcoma (25% vs 16%), was more common among Black patients, and endometrioid was less common (17% vs 48%) (p < 0.01). Differences in gene mutations between cohorts corresponded to observed histologic differences between races. Specifically, TP53 mutations were predominant in serous tumors. In endometrioid tumors, mutations in ARID1A were the most common, and high rates of MSI-H, MMRd, and TMB-H were observed. In carcinosarcoma tumors, hormone receptor expression was high in tumors of Black patients (PR 23.4%, ER 30.8%). When stratified by histology, there were no significant differences between tumors from Black and White women.

CONCLUSIONS: This cohort had a high proportion of tumors from Black women. Distinct molecular profiles were driven primarily by more aggressive histologic subtypes among Black women. Continued effort is needed to include Black women and other populations under-represented in EC molecular profiling studies as targeted therapies and personalized medicine become mainstream.

Original language	English (US)
Pages (from-to)	108-116
Number of pages	9
Journal	Gynecologic oncology
Volume	166
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2022.04.014
State	Published - Jul 2022

Bibliographical note

Funding Information:
We thank the physicians who submitted tumor samples and race data from Karmanos Cancer Network (Detroit, MI), West Cancer Center (Memphis, TN), Levine Cancer Institute (Charlotte, NC), University of South Alabama (Mobile, AL), Georgetown University (Washington, DC), and NYCBS (Port Jefferson Station, NY).

Publisher Copyright:
© 2022

Keywords

Disparities
Endometrial cancer
Molecular profiling
Microsatellite Instability
Carcinoma, Endometrioid/genetics
Humans
Endometrial Neoplasms/pathology
Female
Blacks
Mutation
Carcinosarcoma/genetics

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.ygyno.2022.04.014

Find It

Find It at U of M Libraries

Cite this

@article{44c17c54fd8849099a179b1648f3ff88,

title = "Molecular profiles of endometrial cancer tumors among Black patients",

abstract = "OBJECTIVES: Disparate outcomes exist between Black and White patients with endometrial cancer (EC). One contributing factor is the disproportionately low representation of Black patients in clinical trials and in tumor molecular profiling studies. Our objective was to investigate molecular profiles of ECs in a cohort with a high proportion of tumors from Black patients.METHODS: A total of 248 EC samples and self-reported race data were collected from 6 institutions. Comprehensive tumor profiling and analyses were performed by Caris Life Sciences.RESULTS: Tumors from 105 (42%) Black and 143 (58%) White patients were included. Serous histology (58% vs 36%) and carcinosarcoma (25% vs 16%), was more common among Black patients, and endometrioid was less common (17% vs 48%) (p < 0.01). Differences in gene mutations between cohorts corresponded to observed histologic differences between races. Specifically, TP53 mutations were predominant in serous tumors. In endometrioid tumors, mutations in ARID1A were the most common, and high rates of MSI-H, MMRd, and TMB-H were observed. In carcinosarcoma tumors, hormone receptor expression was high in tumors of Black patients (PR 23.4%, ER 30.8%). When stratified by histology, there were no significant differences between tumors from Black and White women.CONCLUSIONS: This cohort had a high proportion of tumors from Black women. Distinct molecular profiles were driven primarily by more aggressive histologic subtypes among Black women. Continued effort is needed to include Black women and other populations under-represented in EC molecular profiling studies as targeted therapies and personalized medicine become mainstream.",

keywords = "Disparities, Endometrial cancer, Molecular profiling, Microsatellite Instability, Carcinoma, Endometrioid/genetics, Humans, Endometrial Neoplasms/pathology, Female, Blacks, Mutation, Carcinosarcoma/genetics",

author = "Wilhite, {Annelise M.} and Yasmine Baca and Joanne Xiu and Rajesh Paladugu and ElNaggar, {Adam C.} and Jubilee Brown and Winer, {Ira S.} and Robert Morris and Erickson, {Britt K.} and Olawaiye, {Alexander B.} and Matthew Powell and Korn, {W. Michael} and Rocconi, {Rodney P.} and Dineo Khabele and Jones, {Nathaniel L.}",

note = "Funding Information: We thank the physicians who submitted tumor samples and race data from Karmanos Cancer Network (Detroit, MI), West Cancer Center (Memphis, TN), Levine Cancer Institute (Charlotte, NC), University of South Alabama (Mobile, AL), Georgetown University (Washington, DC), and NYCBS (Port Jefferson Station, NY). Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jul,

doi = "10.1016/j.ygyno.2022.04.014",

language = "English (US)",

volume = "166",

pages = "108--116",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Molecular profiles of endometrial cancer tumors among Black patients

AU - Wilhite, Annelise M.

AU - Baca, Yasmine

AU - Xiu, Joanne

AU - Paladugu, Rajesh

AU - ElNaggar, Adam C.

AU - Brown, Jubilee

AU - Winer, Ira S.

AU - Morris, Robert

AU - Erickson, Britt K.

AU - Olawaiye, Alexander B.

AU - Powell, Matthew

AU - Korn, W. Michael

AU - Rocconi, Rodney P.

AU - Khabele, Dineo

AU - Jones, Nathaniel L.

N1 - Funding Information: We thank the physicians who submitted tumor samples and race data from Karmanos Cancer Network (Detroit, MI), West Cancer Center (Memphis, TN), Levine Cancer Institute (Charlotte, NC), University of South Alabama (Mobile, AL), Georgetown University (Washington, DC), and NYCBS (Port Jefferson Station, NY). Publisher Copyright: © 2022

PY - 2022/7

Y1 - 2022/7

N2 - OBJECTIVES: Disparate outcomes exist between Black and White patients with endometrial cancer (EC). One contributing factor is the disproportionately low representation of Black patients in clinical trials and in tumor molecular profiling studies. Our objective was to investigate molecular profiles of ECs in a cohort with a high proportion of tumors from Black patients.METHODS: A total of 248 EC samples and self-reported race data were collected from 6 institutions. Comprehensive tumor profiling and analyses were performed by Caris Life Sciences.RESULTS: Tumors from 105 (42%) Black and 143 (58%) White patients were included. Serous histology (58% vs 36%) and carcinosarcoma (25% vs 16%), was more common among Black patients, and endometrioid was less common (17% vs 48%) (p < 0.01). Differences in gene mutations between cohorts corresponded to observed histologic differences between races. Specifically, TP53 mutations were predominant in serous tumors. In endometrioid tumors, mutations in ARID1A were the most common, and high rates of MSI-H, MMRd, and TMB-H were observed. In carcinosarcoma tumors, hormone receptor expression was high in tumors of Black patients (PR 23.4%, ER 30.8%). When stratified by histology, there were no significant differences between tumors from Black and White women.CONCLUSIONS: This cohort had a high proportion of tumors from Black women. Distinct molecular profiles were driven primarily by more aggressive histologic subtypes among Black women. Continued effort is needed to include Black women and other populations under-represented in EC molecular profiling studies as targeted therapies and personalized medicine become mainstream.

AB - OBJECTIVES: Disparate outcomes exist between Black and White patients with endometrial cancer (EC). One contributing factor is the disproportionately low representation of Black patients in clinical trials and in tumor molecular profiling studies. Our objective was to investigate molecular profiles of ECs in a cohort with a high proportion of tumors from Black patients.METHODS: A total of 248 EC samples and self-reported race data were collected from 6 institutions. Comprehensive tumor profiling and analyses were performed by Caris Life Sciences.RESULTS: Tumors from 105 (42%) Black and 143 (58%) White patients were included. Serous histology (58% vs 36%) and carcinosarcoma (25% vs 16%), was more common among Black patients, and endometrioid was less common (17% vs 48%) (p < 0.01). Differences in gene mutations between cohorts corresponded to observed histologic differences between races. Specifically, TP53 mutations were predominant in serous tumors. In endometrioid tumors, mutations in ARID1A were the most common, and high rates of MSI-H, MMRd, and TMB-H were observed. In carcinosarcoma tumors, hormone receptor expression was high in tumors of Black patients (PR 23.4%, ER 30.8%). When stratified by histology, there were no significant differences between tumors from Black and White women.CONCLUSIONS: This cohort had a high proportion of tumors from Black women. Distinct molecular profiles were driven primarily by more aggressive histologic subtypes among Black women. Continued effort is needed to include Black women and other populations under-represented in EC molecular profiling studies as targeted therapies and personalized medicine become mainstream.

KW - Disparities

KW - Endometrial cancer

KW - Molecular profiling

KW - Microsatellite Instability

KW - Carcinoma, Endometrioid/genetics

KW - Humans

KW - Endometrial Neoplasms/pathology

KW - Female

KW - Blacks

KW - Mutation

KW - Carcinosarcoma/genetics

UR - http://www.scopus.com/inward/record.url?scp=85130027749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130027749&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2022.04.014

DO - 10.1016/j.ygyno.2022.04.014

M3 - Article

C2 - 35490034

AN - SCOPUS:85130027749

SN - 0090-8258

VL - 166

SP - 108

EP - 116

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 1

ER -

Molecular profiles of endometrial cancer tumors among Black patients

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this